AU2015374468A1 - Use of 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism - Google Patents
Use of 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism Download PDFInfo
- Publication number
- AU2015374468A1 AU2015374468A1 AU2015374468A AU2015374468A AU2015374468A1 AU 2015374468 A1 AU2015374468 A1 AU 2015374468A1 AU 2015374468 A AU2015374468 A AU 2015374468A AU 2015374468 A AU2015374468 A AU 2015374468A AU 2015374468 A1 AU2015374468 A1 AU 2015374468A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- secondary hyperparathyroidism
- administered
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 title claims description 88
- UHMPCVGLSKFXHR-NFZXMVPNSA-N (1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 UHMPCVGLSKFXHR-NFZXMVPNSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000002092 calcimimetic effect Effects 0.000 claims description 53
- 210000002966 serum Anatomy 0.000 claims description 52
- 208000024891 symptom Diseases 0.000 claims description 42
- 229960005084 calcitriol Drugs 0.000 claims description 35
- 208000020832 chronic kidney disease Diseases 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 21
- 230000000148 hypercalcaemia Effects 0.000 claims description 21
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 13
- 239000011574 phosphorus Substances 0.000 claims description 13
- 229940109239 creatinine Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000001631 haemodialysis Methods 0.000 claims description 6
- 230000000322 hemodialysis Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 3
- 239000011575 calcium Substances 0.000 description 50
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 49
- 229910052791 calcium Inorganic materials 0.000 description 48
- 239000003814 drug Substances 0.000 description 42
- 102000003982 Parathyroid hormone Human genes 0.000 description 41
- 108090000445 Parathyroid hormone Proteins 0.000 description 41
- 229940079593 drug Drugs 0.000 description 41
- 239000000199 parathyroid hormone Substances 0.000 description 41
- 229960001319 parathyroid hormone Drugs 0.000 description 41
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 24
- 235000020964 calcitriol Nutrition 0.000 description 24
- 239000011612 calcitriol Substances 0.000 description 24
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 229930003316 Vitamin D Natural products 0.000 description 22
- 235000019166 vitamin D Nutrition 0.000 description 22
- 239000011710 vitamin D Substances 0.000 description 22
- 229940046008 vitamin d Drugs 0.000 description 22
- 239000003826 tablet Substances 0.000 description 21
- 229940090044 injection Drugs 0.000 description 19
- 208000017169 kidney disease Diseases 0.000 description 18
- 210000002990 parathyroid gland Anatomy 0.000 description 18
- 150000003710 vitamin D derivatives Chemical class 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000013265 extended release Methods 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 11
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 11
- 239000005414 inactive ingredient Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 208000001647 Renal Insufficiency Diseases 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 229960003315 cinacalcet Drugs 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 201000006370 kidney failure Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- -1 vitamin D compounds Chemical class 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 229950006319 maxacalcitol Drugs 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000007909 solid dosage form Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 6
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 6
- 208000013038 Hypocalcemia Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000000705 hypocalcaemia Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000006208 topical dosage form Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000008299 semisolid dosage form Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 206010051714 Calciphylaxis Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 2
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010070918 Bone deformity Diseases 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- 206010020669 Hypermagnesaemia Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000006670 Multiple fractures Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000000125 calcaemic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000009136 lithium therapy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 229960000987 paricalcitol Drugs 0.000 description 2
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- 201000006409 renal osteodystrophy Diseases 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 201000010384 renal tubular acidosis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000001962 taste-modifying agent Substances 0.000 description 2
- 239000006211 transdermal dosage form Substances 0.000 description 2
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 229940052212 zemplar Drugs 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063544 Renal embolism Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940105640 paricalcitol injection Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000003173 phosphatemic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116949 sensipar Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098112P | 2014-12-30 | 2014-12-30 | |
| US62/098,112 | 2014-12-30 | ||
| US14/710,746 | 2015-05-13 | ||
| US14/710,746 US9539264B2 (en) | 2014-12-30 | 2015-05-13 | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| PCT/US2015/065175 WO2016109156A1 (en) | 2014-12-30 | 2015-12-11 | Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015374468A1 true AU2015374468A1 (en) | 2017-06-22 |
Family
ID=56162990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015374468A Abandoned AU2015374468A1 (en) | 2014-12-30 | 2015-12-11 | Use of 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9539264B2 (enExample) |
| EP (1) | EP3240549A4 (enExample) |
| JP (1) | JP2018500375A (enExample) |
| AU (1) | AU2015374468A1 (enExample) |
| CA (1) | CA2969334A1 (enExample) |
| WO (1) | WO2016109156A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| WO2018044468A1 (en) * | 2016-08-30 | 2018-03-08 | Wisconsin Alumni Research Foundation | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
| US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| EP1267886B1 (en) | 2000-03-27 | 2006-03-08 | Wisconsin Alumni Research Foundation | Vitamin d compounds for the treatment of chronic allograft nephropathy in kidney transplant patients |
| IL153907A0 (en) | 2000-07-14 | 2003-07-31 | Wisconsin Alumni Res Found | PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3 |
| US20080249068A1 (en) | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US7214671B2 (en) | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| WO2006086613A2 (en) | 2005-02-11 | 2006-08-17 | Wisconsin Alumni Research Foundation | 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2 |
| MX2007011153A (es) | 2005-03-17 | 2007-12-12 | Amgen Inc | Metodos para reducir la calcificacion. |
| EP2001832A1 (en) * | 2006-03-23 | 2008-12-17 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| EP3225243B1 (en) * | 2007-04-25 | 2025-09-03 | Opko Renal, LLC | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| CA2764577C (en) | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| EP2556053B1 (en) | 2010-03-23 | 2015-07-29 | Wisconsin Alumni Research Foundation | (20s)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1alpha,25-hydroxyvitamin d3 |
| AU2012335009B2 (en) | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| US20130295083A1 (en) | 2012-05-02 | 2013-11-07 | Wisconsin Alumni Research Foundation | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes |
| EP2866811A1 (en) | 2012-06-29 | 2015-05-06 | Wisconsin Alumni Research Foundation | USE OF 2-METHYLENE-19-NOR-(20S)-1 alpha,25-DIHYDROXYVITAMIN D³ TO TREAT SECONDARY HYPERPARATHYROIDISM |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
-
2015
- 2015-05-13 US US14/710,746 patent/US9539264B2/en not_active Expired - Fee Related
- 2015-12-11 WO PCT/US2015/065175 patent/WO2016109156A1/en not_active Ceased
- 2015-12-11 CA CA2969334A patent/CA2969334A1/en not_active Abandoned
- 2015-12-11 JP JP2017534946A patent/JP2018500375A/ja active Pending
- 2015-12-11 EP EP15875945.6A patent/EP3240549A4/en not_active Withdrawn
- 2015-12-11 AU AU2015374468A patent/AU2015374468A1/en not_active Abandoned
-
2016
- 2016-10-31 US US15/338,924 patent/US9814736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9539264B2 (en) | 2017-01-10 |
| JP2018500375A (ja) | 2018-01-11 |
| EP3240549A1 (en) | 2017-11-08 |
| CA2969334A1 (en) | 2016-07-07 |
| WO2016109156A1 (en) | 2016-07-07 |
| US20170042913A1 (en) | 2017-02-16 |
| EP3240549A4 (en) | 2018-08-29 |
| US20160184328A1 (en) | 2016-06-30 |
| US9814736B2 (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10046000B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure | |
| JP6375353B2 (ja) | ２５−ヒドロキシビタミンｄ３を含む経口剤形、及び、その経口剤形を週１回ヒトに投与することを含む方法 | |
| CA2777938C (en) | Method of preventing type 1 diabetes | |
| US9814736B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| US10369161B2 (en) | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION Free format text: FORMER NAME(S): WISCONSIN ALUMNI RESEARCH FOUNDATION; HECTOR F. DELUCA; LORI A. PLUM; MARGARET CLAGETT-DAME |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |